Equities analysts expect TherapeuticsMD Inc (NASDAQ:TXMD) to post $4.59 million in sales for the current fiscal quarter, according to Zacks Investment Research. Four analysts have made estimates for TherapeuticsMD’s earnings, with the highest sales estimate coming in at $5.09 million and the lowest estimate coming in at $4.22 million. TherapeuticsMD posted sales of $4.42 million in the same quarter last year, which suggests a positive year-over-year growth rate of 3.8%. The business is expected to report its next quarterly earnings results on Monday, November 5th.

According to Zacks, analysts expect that TherapeuticsMD will report full-year sales of $19.06 million for the current year, with estimates ranging from $17.47 million to $20.70 million. For the next fiscal year, analysts forecast that the company will report sales of $128.64 million, with estimates ranging from $74.00 million to $180.20 million. Zacks’ sales calculations are an average based on a survey of sell-side research firms that that provide coverage for TherapeuticsMD.

TherapeuticsMD (NASDAQ:TXMD) last announced its quarterly earnings data on Monday, July 30th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.12) by ($0.03). The firm had revenue of $3.80 million during the quarter, compared to the consensus estimate of $4.23 million. TherapeuticsMD had a negative net margin of 582.86% and a negative return on equity of 80.75%. The company’s revenue was down 11.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.10) earnings per share.

A number of research firms have weighed in on TXMD. Zacks Investment Research raised TherapeuticsMD from a “sell” rating to a “hold” rating in a report on Saturday, August 25th. ValuEngine lowered TherapeuticsMD from a “buy” rating to a “hold” rating in a report on Saturday, July 28th. BidaskClub lowered TherapeuticsMD from a “sell” rating to a “strong sell” rating in a report on Wednesday, August 1st. Cantor Fitzgerald lifted their target price on TherapeuticsMD from $26.00 to $27.00 and gave the company an “overweight” rating in a report on Tuesday, August 14th. Finally, Oppenheimer set a $14.00 price objective on TherapeuticsMD and gave the stock a “buy” rating in a report on Monday, August 13th. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. TherapeuticsMD has an average rating of “Buy” and an average target price of $15.40.

TXMD stock traded up $0.10 during mid-day trading on Friday, reaching $5.98. 111,881 shares of the company traded hands, compared to its average volume of 2,511,643. The company has a quick ratio of 7.79, a current ratio of 7.88 and a debt-to-equity ratio of 0.94. The firm has a market capitalization of $1.52 billion, a PE ratio of -16.00 and a beta of 1.40. TherapeuticsMD has a 52-week low of $4.34 and a 52-week high of $7.66.

In other TherapeuticsMD news, CEO Robert G. Finizio sold 184,000 shares of the business’s stock in a transaction that occurred on Friday, September 7th. The stock was sold at an average price of $6.24, for a total value of $1,148,160.00. Following the completion of the sale, the chief executive officer now owns 18,485,559 shares in the company, valued at $115,349,888.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider John C.K. Iv Milligan sold 125,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 26th. The shares were sold at an average price of $6.78, for a total value of $847,500.00. Following the completion of the sale, the insider now owns 1,597,419 shares of the company’s stock, valued at approximately $10,830,500.82. The disclosure for this sale can be found here. Insiders sold 1,108,600 shares of company stock valued at $7,096,872 in the last quarter. Corporate insiders own 22.85% of the company’s stock.

Hedge funds have recently made changes to their positions in the business. Swiss National Bank raised its holdings in shares of TherapeuticsMD by 4.0% during the first quarter. Swiss National Bank now owns 301,400 shares of the company’s stock valued at $1,468,000 after acquiring an additional 11,600 shares in the last quarter. Schwab Charles Investment Management Inc. raised its holdings in shares of TherapeuticsMD by 5.0% during the first quarter. Schwab Charles Investment Management Inc. now owns 859,997 shares of the company’s stock valued at $4,189,000 after acquiring an additional 40,954 shares in the last quarter. New York State Common Retirement Fund raised its holdings in shares of TherapeuticsMD by 7.3% during the first quarter. New York State Common Retirement Fund now owns 255,339 shares of the company’s stock valued at $1,244,000 after acquiring an additional 17,400 shares in the last quarter. Stifel Financial Corp raised its holdings in shares of TherapeuticsMD by 1.3% during the first quarter. Stifel Financial Corp now owns 1,862,644 shares of the company’s stock valued at $9,067,000 after acquiring an additional 23,141 shares in the last quarter. Finally, GSA Capital Partners LLP raised its holdings in shares of TherapeuticsMD by 274.8% during the first quarter. GSA Capital Partners LLP now owns 117,700 shares of the company’s stock valued at $573,000 after acquiring an additional 86,300 shares in the last quarter. Hedge funds and other institutional investors own 66.14% of the company’s stock.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a women's health care product company. Its pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen.

Featured Article: How to Invest in Marijuana Stocks

Get a free copy of the Zacks research report on TherapeuticsMD (TXMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.